Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Venous Thrombosis 2Thromboembolism 2Neoplasms 2Vulvar Neoplasms 1Venous Thromboembolism 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thrombosis 1Sarcoma 1Pulmonary Embolism 1Postoperative Complications 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Radiotherapy, Intensity-Modulated 1Radiotherapy 1Oxaliplatin 1Mammaplasty 1Intermittent Pneumatic Compression Devices 1Fondaparinux 1Fibrin Tissue Adhesive 1Educational Status 1Dexamethasone 1Counseling 1Cathartics 1Carbohydrates 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Postoperative Complications × Fondaparinux × Clear all
NCT00539942 2017-03-27

Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy

University of Alabama at Birmingham

Phase 3 Terminated
7 enrolled 9 charts

Postoperative Complications, Venous Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡